Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.9K
Clinical Trials01:16

Clinical Trials

9.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Cancer Therapies02:49

Cancer Therapies

8.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Technical Considerations on Proton Therapy in NRG's Multi-Institutional Clinical Trials.

International journal of radiation oncology, biology, physics·2026
Same author

C. Norman Coleman's Legacy in Radiation Research and Global Health: A Cancer Research and Care Perspective.

Disaster medicine and public health preparedness·2026
Same author

Re-envisioning the North American Biodosimetry Assessment Networking Group.

Disaster medicine and public health preparedness·2026
Same author

Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth.

Cancer cell·2026
Same author

Reirradiation Collaborative Group (ReCOG) consensus on standards for dose evaluation and reporting in patients with multiple courses of radiation therapy: an AAPM/ACRO/ASTRO/CARO/COMP/CADRA/CPQR/ESTRO/NRG-endorsed consensus statement.

The Lancet. Oncology·2026
Same author

Erratum to Xiao Y, Benedict S, Cui Y, Glide-Hurst C, Graves S, Jia X, KryF S, Li H, Lin L, Matuszak M, Newpower M, Paganetti H, Qi XS, Roncali E, Rong Y, Sgouros G, Simone 2nd CB, Sunderland JJ, Taylor PA, Tchelebi L, Weldon M, Zou JW, Wuthrick EJ, Machtay M, Le QT, Buchsbaum JC. Embracing the future of clinical trials in radiation therapy: an NRG oncology CIRO technology retreat whitepaper on pioneering technologies and AI-driven solutions. Int J of Radiat Oncol Biol Phys 2025:122;443-457.

International journal of radiation oncology, biology, physics·2026

Related Experiment Video

Updated: Oct 25, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.4K

Overview and Lessons From the Preclinical Chemoradiotherapy Testing Consortium.

Jeffrey C Buchsbaum1, C Norman Coleman1, Eric J Bernhard1

  • 1Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

International Journal of Radiation Oncology, Biology, Physics
|August 4, 2021
PubMed
Summary

The Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC) generates data to prioritize molecular agents for combined cancer therapy. This accelerates the identification of effective chemoradiotherapy treatments for improved patient outcomes.

More Related Videos

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.8K
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

10.0K

Related Experiment Videos

Last Updated: Oct 25, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.4K
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.8K
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

10.0K

Area of Science:

  • Oncology
  • Cancer Therapeutics
  • Radiation Oncology

Background:

  • Optimizing molecular-targeted cancer therapy combined with radiation is complex.
  • Emerging laboratory technologies are crucial for understanding drug-radiation mechanisms.
  • The National Cancer Institute (NCI) initiated research to combine targeted agents with chemoradiation.

Purpose of the Study:

  • To establish the Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC).
  • To generate validated preclinical data on molecular therapeutics combined with standard-of-care therapies.
  • To focus on cancers of the pancreas, lung, head and neck, gastrointestinal tract, and brain.

Main Methods:

  • Formation of the PCRTC with 4 U01 programs.
  • Generation of high-quality preclinical data.
  • Testing molecular therapeutics in combination with chemoradiotherapy.

Main Results:

  • The PCRTC provides a rational basis for prioritizing NCI-supported investigational drugs.
  • Identifies agents most likely to have clinical activity with chemoradiotherapy.
  • Accelerates the identification of effective combined modality treatments.

Conclusions:

  • The PCRTC summarizes its progress and preliminary findings.
  • The consortium's work aims to enhance the efficiency of preclinical to clinical progression.
  • Preliminary observations guide the prioritization of novel cancer therapies.